Evidence map›Paper›PMID 12923212›Full record

ArticleThe Journal of physiology2003

Oestrogen effects on urine concentrating response in young women.

Nina S Stachenfeld, Hugh S Taylor, Cheryl A Leone, David L Keefe

Open access · greenAbstract read
In one paragraph

Article in The Journal of physiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
  7. Race, sex, and the regulation of urine osmolality: observations made during water deprivation.American journal of physiology. Regulatory, integrative and comparative physiology · 2010
    Article
  8. Article
  9. Article
  10. Sex hormone effects on body fluid regulation.Exercise and sport sciences reviews · 2008
    Article
  11. Vasopressin directly regulates cyst growth in polycystic kidney disease.Journal of the American Society of Nephrology : JASN · 2008
    Article
  12. Phase of the menstrual cycle does not affect orthostatic tolerance in healthy women.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2006
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nina S StachenfeldThe John B. Pierce Laboratory, New Haven, CT 06519, USA. nstach@jbpierce.org
Hugh S Taylor
Cheryl A Leone
David L Keefe
John B. Pierce Laboratory · USBrown University · US

Funding

SEX HORMONES AND BODY FLUID REGULATIONR01HL062240 · NHLBI · JOHN B. PIERCE LABORATORY, INC. · PI STACHENFELD, NINA · 2000 to 2003
$1.1M
NHLBI NIH HHS R01 HL062240NHLBI NIH HHS R01 HL62240-01A1
6 · The paper itself

Abstract

Oestrogen lowers the plasma osmotic threshold for arginine vasopressin (AVP) release but without commensurate changes in renal concentrating response, suggesting oestrogen (OE2) may lower renal sensitivity to AVP. Ten women (23 +/- 1 years) received a gonadotropin releasing hormone analogue (GnRHa), leuprolide acetate, to suppress OE2 for 35 days, and then added OE2 (two patches each delivering 0.1 mg day-1) on days 32-35. On days 28 and 35 we tested blood and renal water and sodium (Na+) regulation during stepwise 60 min AVP infusions (10, 35, 100, 150 and 200 microu (kg body weight)-1 Pitressin). Plasma OE2 concentration increased from 19 +/- 4 to 152 +/- 3 pg ml(-1) and plasma progesterone concentration was unchanged (1.0 +/- 0.4 and 0.7 +/- 0.1 ng ml(-1)) for GnRHa and OE2 administration, respectively. Standard log plots of plasma AVP concentration ([AVP]P) vs. urine osmolality (OsmU) were fitted to a sigmoidal curve, and EC50 was determined by non-linear regression curve fitting of concentration-response data. OsmU rose exponentially during AVP infusions, but hormone treatments did not affect EC50 (3.3 +/- 0.07 and 3.1 +/- 0.6 pg ml(-1), for GnRHa and OE2, respectively). However, the urine osmolality increase was greater within the physiological range (approximately 2.5-3.4 pg ml(-1) [AVP]P) during OE2 treatment. Throughout most of the AVP infusion, the rate of clearance of AVP from plasma (PCRAVP) was increased during OE2 (45.5 ml (kg body weight)(-1) min(-1)) compared to GnRHa administration (33.1 ml (kg body weight)(-1) min(-1); mean for the 100-200 microu (kg body weight)(-1) infusion rates). The rate of renal free water clearance (CH2O) was similar between hormone treatments. Sodium excretion fell during OE2 administration due to greater distal tubular sodium reabsorption. Despite more rapid PCRAVP, renal concentrating response to graded AVP infusions was unaffected by oestrogen treatment suggesting oestrogen does not affect overall renal sensitivity to AVP. However, OE2 may increase renal fluid retention within a physiological range of AVP.

Indexed as

Administration, CutaneousAdultArginine VasopressinBody WaterDose-Response Relationship, DrugEstrogen AntagonistsEstrogensFemaleGonadotropin-Releasing HormoneHumansKidneyKidney Concentrating AbilityLeuprolideNatriuresisOsmolar ConcentrationUrineArginine VasopressinEstrogen AntagonistsEstrogensGonadotropin-Releasing HormoneLeuprolide

Identifiers

PMID12923212
PMCPMC2343447
OpenAlexW2118494558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.